Vertex Pharmaceuticals (VRTX) announced Tuesday night the design of two phase III studies for its combination therapy to treat the most common form of cystic fibrosis. The studies will each run for six months, so results could be ready as early as the end of 2013 or during first half of 2014.
If the studies are positive, Vertex intends to file for U.S. approval in 2014. Continue reading Vertex Readies Late-Stage Cystic Fibrosis Drug Studies
Promising pre-clinical data in Cystic Fibrosis for ProtAffin AGs PA401 to be presented at ATS, Philadelphia, 17-22 May 2013
ProtAffin AG, a biotechnology company developing a novel class of next-generation biopharmaceuticals for inflammation, respiratory disease and oncology, has announced that a collaboration with a leading European centre for the study of cystic fibrosis has generated Continue reading Pharma And Biotech
Many manufacturers of medications used by CF patients offer patient assistance programs to assist individuals with insufficient or no insurance coverage to obtain medications. Programs vary in their offerings from sampling products, providing nutritional supplements, and co-pay assistance.
Digestive Enzymes Continue reading Saving Money with Patient Assistance Programs
My wife is a mental health therapist. She talks to people all day long about their problems. She has countless hours of experience dealing with people and their behaviors. One day, after apparently meeting with a client who was having trouble because they were not taking their prescribed Continue reading Compliance–Guest Blog By Mark Levine
I feel good. That may not seem like such a big deal to most people, but it is to me. For the past two-and-a-half years I have not been feeling very well. First I had pneumonia in both lungs. Then I had a twist in my small intestines. The pneumonia never quite went away and my Continue reading Feeling Good!–Guest Blog by Kathy Russell
OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant enables OrPro to advance development of its lead product, Continue reading OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis